SCHEMBL1127419

SCHEMBL1127419

CS(=O)(=O)c1ccc(CC(C(=O)O)c2ccccn2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGS1 P23219 2/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
PTGS2 P35354 1/20 0.40
CYP2C19 P33261 1/20 0.40
ITGB1 P05556 1/20 0.39
ITGA4 P13612 1/20 0.39
P4HTM Q9NXG6 1/20 0.39
PTPRA P18433 1/20 0.38
GPR39 O43194 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
PGR P06401 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
SLC6A2 P23975 1/20 0.38
MAPK8 P45983 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127873 0.85 MEN1 (0.49) KDM4EALDH1A1MEN1KMT2APTGS1
SCHEMBL1127361 0.84 CYP1A2 (0.53) ALDH1A1CYP1A2PTGS1CYP2C19P4HTM
SCHEMBL1127436 0.81 MEN1 (0.46) KDM4EALDH1A1MEN1KMT2APTGS1
SCHEMBL1127590 0.81 KMT2A (0.46) CYP1A2KMT2AP4HTMSLC6A2
SCHEMBL1127442 0.80 KDM4E (0.37) KDM4EALDH1A1CYP1A2MEN1KMT2A
SCHEMBL13662208 0.77 KDM4E (0.43) KDM4EMEN1KMT2APTGS1PTGS2
SCHEMBL1127294 0.75 MME (0.41) ALDH1A1CYP1A2PTGDR2CYP2C19P4HTM
SCHEMBL1127686 0.74 PTPRA (0.41) KDM4EALDH1A1CYP1A2CYP2C19P4HTM
SCHEMBL2680153 0.74 ALDH1A1 (0.55) KDM4EALDH1A1CYP1A2MEN1KMT2A
SCHEMBL15647871 0.73 LDHA (0.55) PTGS1PTGS2ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF KDM4E 1012/4885ALDH1A1 1614/4885CYP1A2 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.